Last reviewed · How we verify

Intranasal Budesonide Spray

Second Xiangya Hospital of Central South University · Phase 3 active Small molecule

Budesonide is a corticosteroid that reduces inflammation in the nasal airways by suppressing immune cell activation and inflammatory mediator release.

Budesonide is a corticosteroid that reduces inflammation in the nasal airways by suppressing immune cell activation and inflammatory mediator release. Used for Allergic rhinitis, Nasal inflammation and congestion.

At a glance

Generic nameIntranasal Budesonide Spray
SponsorSecond Xiangya Hospital of Central South University
Drug classIntranasal corticosteroid
TargetGlucocorticoid receptor
ModalitySmall molecule
Therapeutic areaImmunology / Allergy / Respiratory
PhasePhase 3

Mechanism of action

Budesonide binds to glucocorticoid receptors in nasal tissue, leading to decreased production of inflammatory cytokines, reduced recruitment of immune cells, and stabilization of mast cells. This results in reduced nasal inflammation, congestion, and allergic symptoms. The intranasal formulation delivers the drug directly to the site of inflammation while minimizing systemic exposure.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: